Torii to Sell Futhan to Nichi-Iko after 43% Off-Patent Price Slash

February 7, 2019
Torii Pharmaceutical is offloading its mainstay protease inhibitor Futhan (nafamostat) to Big 3 Japanese generic maker Nichi-Iko Pharmaceutical after the drug faced a hefty 43.4% price cut in April last year under a revamped re-pricing scheme for off-patent brand-name drugs...read more